Thermo Fisher Scientific (TMO) Showcases Diagnostics Momentum, Is The Valuation Upside Already Priced In?

Thermo Fisher Scientific (TMO) recently highlighted its specialty diagnostics business, including new products and FDA clearances, following a period of strong stock performance with significant share price returns over the last year. While a popular narrative suggests the stock is slightly overvalued at $594 compared to a fair value of $590.77, based on its growth in innovation, a discounted cash flow model indicates it might be undervalued by 7.3% at $640.50. Investors are encouraged to review the underlying data to assess the balance between the company's innovation momentum and potential valuation concerns.